Annual FCF
-$193.47 M
+$116.21 M+37.53%
31 December 2023
Summary:
Nektar Therapeutics annual free cash flow is currently -$193.47 million, with the most recent change of +$116.21 million (+37.53%) on 31 December 2023. During the last 3 years, it has risen by +$127.07 million (+39.64%). NKTR annual FCF is now -127.48% below its all-time high of $703.98 million, reached on 31 December 2018.NKTR Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$44.60 M
-$6.71 M-17.71%
30 September 2024
Summary:
Nektar Therapeutics quarterly free cash flow is currently -$44.60 million, with the most recent change of -$6.71 million (-17.71%) on 30 September 2024. Over the past year, it has dropped by -$2.44 million (-5.80%). NKTR quarterly FCF is now -104.66% below its all-time high of $956.90 million, reached on 30 June 2018.NKTR Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$177.81 M
-$2.44 M-1.39%
30 September 2024
Summary:
Nektar Therapeutics TTM free cash flow is currently -$177.81 million, with the most recent change of -$2.44 million (-1.39%) on 30 September 2024. Over the past year, it has increased by +$26.59 million (+13.01%). NKTR TTM FCF is now -119.48% below its all-time high of $912.79 million, reached on 30 June 2018.NKTR TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +37.5% | -5.8% | +13.0% |
| 3 y3 years | +39.6% | +57.1% | +52.0% |
| 5 y5 years | -127.5% | +39.7% | +49.5% |
NKTR Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.8% | -17.7% | +71.7% | -1.4% | +59.6% |
| 5 y | 5 years | -127.5% | +54.8% | -17.7% | +71.7% | -1.4% | +59.6% |
| alltime | all time | -127.5% | +54.8% | -104.7% | +71.7% | -119.5% | +59.6% |
Nektar Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$44.60 M(+17.7%) | -$177.81 M(+1.4%) |
| June 2024 | - | -$37.89 M(-21.1%) | -$175.37 M(-7.3%) |
| Mar 2024 | - | -$48.05 M(+1.6%) | -$189.17 M(-2.2%) |
| Dec 2023 | -$193.47 M(-37.5%) | -$47.28 M(+12.2%) | -$193.47 M(-5.3%) |
| Sept 2023 | - | -$42.15 M(-18.4%) | -$204.40 M(-16.7%) |
| June 2023 | - | -$51.69 M(-1.3%) | -$245.32 M(-8.9%) |
| Mar 2023 | - | -$52.35 M(-10.1%) | -$269.40 M(-13.0%) |
| Dec 2022 | -$309.68 M(-27.6%) | -$58.22 M(-29.9%) | -$309.68 M(-24.3%) |
| Sept 2022 | - | -$83.07 M(+9.6%) | -$408.90 M(-4.9%) |
| June 2022 | - | -$75.77 M(-18.2%) | -$429.91 M(-2.4%) |
| Mar 2022 | - | -$92.63 M(-41.2%) | -$440.31 M(+3.0%) |
| Dec 2021 | -$427.65 M(+33.4%) | -$157.43 M(+51.3%) | -$427.65 M(+15.4%) |
| Sept 2021 | - | -$104.07 M(+20.8%) | -$370.60 M(+15.4%) |
| June 2021 | - | -$86.18 M(+7.8%) | -$321.12 M(-0.1%) |
| Mar 2021 | - | -$79.96 M(-20.3%) | -$321.53 M(+0.3%) |
| Dec 2020 | -$320.55 M(-9.7%) | -$100.39 M(+83.9%) | -$320.55 M(-8.2%) |
| Sept 2020 | - | -$54.59 M(-37.0%) | -$349.05 M(-5.3%) |
| June 2020 | - | -$86.60 M(+9.7%) | -$368.43 M(+6.1%) |
| Mar 2020 | - | -$78.97 M(-38.7%) | -$347.40 M(-2.1%) |
| Dec 2019 | -$354.97 M(-150.4%) | -$128.89 M(+74.3%) | -$354.97 M(+0.8%) |
| Sept 2019 | - | -$73.96 M(+12.8%) | -$352.31 M(+0.2%) |
| June 2019 | - | -$65.56 M(-24.2%) | -$351.58 M(-152.4%) |
| Mar 2019 | - | -$86.54 M(-31.4%) | $670.88 M(-4.7%) |
| Dec 2018 | $703.98 M(-881.4%) | -$126.24 M(+72.4%) | $703.98 M(-5.8%) |
| Sept 2018 | - | -$73.23 M(-107.7%) | $747.42 M(-18.1%) |
| June 2018 | - | $956.90 M(-1890.2%) | $912.79 M(-970.3%) |
| Mar 2018 | - | -$53.45 M(-35.4%) | -$104.89 M(+16.4%) |
| Dec 2017 | -$90.09 M(-27.0%) | -$82.79 M(-189.9%) | -$90.09 M(+44.5%) |
| Sept 2017 | - | $92.14 M(-251.6%) | -$62.36 M(-65.8%) |
| June 2017 | - | -$60.78 M(+57.2%) | -$182.36 M(+33.4%) |
| Mar 2017 | - | -$38.66 M(-29.8%) | -$136.74 M(+10.8%) |
| Dec 2016 | -$123.42 M(+46.4%) | -$55.06 M(+97.6%) | -$123.42 M(-15.4%) |
| Sept 2016 | - | -$27.87 M(+83.8%) | -$145.94 M(+7.1%) |
| June 2016 | - | -$15.16 M(-40.1%) | -$136.24 M(-20.7%) |
| Mar 2016 | - | -$25.33 M(-67.4%) | -$171.86 M(+103.9%) |
| Dec 2015 | -$84.28 M(-44.5%) | -$77.58 M(+327.0%) | -$84.28 M(+139.4%) |
| Sept 2015 | - | -$18.17 M(-64.2%) | -$35.21 M(-44.9%) |
| June 2015 | - | -$50.78 M(-181.6%) | -$63.94 M(+179.0%) |
| Mar 2015 | - | $62.25 M(-318.3%) | -$22.91 M(-84.9%) |
| Dec 2014 | -$151.98 M(+256.6%) | -$28.51 M(-39.2%) | -$151.98 M(+109.5%) |
| Sept 2014 | - | -$46.90 M(+380.9%) | -$72.55 M(+57.9%) |
| June 2014 | - | -$9.75 M(-85.4%) | -$45.94 M(-35.3%) |
| Mar 2014 | - | -$66.81 M(-231.2%) | -$71.00 M(+66.6%) |
| Dec 2013 | -$42.62 M(-69.6%) | $50.92 M(-350.9%) | -$42.62 M(-70.8%) |
| Sept 2013 | - | -$20.30 M(-41.7%) | -$145.75 M(-6.1%) |
| June 2013 | - | -$34.81 M(-9.4%) | -$155.20 M(+8.8%) |
| Mar 2013 | - | -$38.43 M(-26.4%) | -$142.63 M(+1.6%) |
| Dec 2012 | -$140.34 M(+13.7%) | -$52.22 M(+75.6%) | -$140.34 M(+6.5%) |
| Sept 2012 | - | -$29.74 M(+33.7%) | -$131.77 M(+5.1%) |
| June 2012 | - | -$22.25 M(-38.4%) | -$125.34 M(-11.1%) |
| Mar 2012 | - | -$36.13 M(-17.2%) | -$140.96 M(+14.2%) |
| Dec 2011 | -$123.46 M(+41.4%) | -$43.64 M(+87.2%) | -$123.46 M(+79.7%) |
| Sept 2011 | - | -$23.32 M(-38.4%) | -$68.71 M(-15.1%) |
| June 2011 | - | -$37.87 M(+103.2%) | -$80.92 M(+19.3%) |
| Mar 2011 | - | -$18.64 M(-267.7%) | -$67.83 M(-22.3%) |
| Dec 2010 | -$87.33 M(-558.7%) | $11.11 M(-131.3%) | -$87.33 M(-500.3%) |
| Sept 2010 | - | -$35.53 M(+43.4%) | $21.82 M(-38.0%) |
| June 2010 | - | -$24.78 M(-35.0%) | $35.20 M(+24.0%) |
| Mar 2010 | - | -$38.14 M(-131.7%) | $28.40 M(+49.2%) |
| Dec 2009 | $19.04 M | $120.25 M(-643.1%) | $19.04 M(-114.0%) |
| Sept 2009 | - | -$22.14 M(-29.9%) | -$135.72 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$31.58 M(-33.5%) | -$136.94 M(-3.5%) |
| Mar 2009 | - | -$47.50 M(+37.6%) | -$141.88 M(-13.8%) |
| Dec 2008 | -$164.64 M(-245.0%) | -$34.51 M(+47.8%) | -$164.64 M(+364.1%) |
| Sept 2008 | - | -$23.36 M(-36.1%) | -$35.47 M(-207.6%) |
| June 2008 | - | -$36.52 M(-48.0%) | $32.96 M(-57.6%) |
| Mar 2008 | - | -$70.25 M(-174.2%) | $77.81 M(-31.5%) |
| Dec 2007 | $113.51 M(-198.5%) | $94.66 M(+110.0%) | $113.51 M(-933.4%) |
| Sept 2007 | - | $45.08 M(+441.6%) | -$13.62 M(-76.7%) |
| June 2007 | - | $8.32 M(-124.1%) | -$58.47 M(-45.1%) |
| Mar 2007 | - | -$34.55 M(+6.4%) | -$106.49 M(-7.6%) |
| Dec 2006 | -$115.24 M(+20.1%) | -$32.47 M(<-9900.0%) | -$115.24 M(+9.1%) |
| Sept 2006 | - | $232.00 K(-100.6%) | -$105.59 M(-21.4%) |
| June 2006 | - | -$39.70 M(-8.3%) | -$134.39 M(+11.7%) |
| Mar 2006 | - | -$43.31 M(+89.8%) | -$120.36 M(+25.4%) |
| Dec 2005 | -$95.95 M(-8.9%) | -$22.82 M(-20.1%) | -$95.95 M(+9.7%) |
| Sept 2005 | - | -$28.57 M(+11.3%) | -$87.44 M(+12.6%) |
| June 2005 | - | -$25.67 M(+35.9%) | -$77.64 M(-15.0%) |
| Mar 2005 | - | -$18.89 M(+32.1%) | -$91.33 M(-13.3%) |
| Dec 2004 | -$105.34 M(+10.9%) | -$14.31 M(-23.8%) | -$105.34 M(-5.7%) |
| Sept 2004 | - | -$18.77 M(-52.3%) | -$111.69 M(+2.5%) |
| June 2004 | - | -$39.37 M(+19.7%) | -$109.01 M(+27.3%) |
| Mar 2004 | - | -$32.90 M(+59.2%) | -$85.61 M(-9.8%) |
| Dec 2003 | -$94.95 M(+4.0%) | -$20.67 M(+28.5%) | -$94.95 M(+4.1%) |
| Sept 2003 | - | -$16.08 M(+0.7%) | -$91.23 M(-8.8%) |
| June 2003 | - | -$15.97 M(-62.2%) | -$100.03 M(-8.9%) |
| Mar 2003 | - | -$42.24 M(+149.2%) | -$109.79 M(+20.2%) |
| Dec 2002 | -$91.30 M(+7.3%) | -$16.95 M(-31.9%) | -$91.30 M(+1.6%) |
| Sept 2002 | - | -$24.89 M(-3.3%) | -$89.88 M(-13.8%) |
| June 2002 | - | -$25.72 M(+8.3%) | -$104.24 M(+21.4%) |
| Mar 2002 | - | -$23.75 M(+53.0%) | -$85.89 M(+0.9%) |
| Dec 2001 | -$85.09 M(-5.0%) | -$15.52 M(-60.5%) | -$85.09 M(+1.9%) |
| Sept 2001 | - | -$39.25 M(+432.0%) | -$83.48 M(+10.3%) |
| June 2001 | - | -$7.38 M(-67.9%) | -$75.67 M(-22.0%) |
| Mar 2001 | - | -$22.95 M(+65.1%) | -$97.07 M(+8.3%) |
| Dec 2000 | -$89.59 M(+150.0%) | -$13.90 M(-55.8%) | -$89.59 M(+4.5%) |
| Sept 2000 | - | -$31.44 M(+9.2%) | -$85.73 M(+55.1%) |
| June 2000 | - | -$28.78 M(+86.0%) | -$55.29 M(+31.7%) |
| Mar 2000 | - | -$15.47 M(+54.2%) | -$41.98 M(+17.1%) |
| Dec 1999 | -$35.84 M(-33.4%) | -$10.04 M(+903.6%) | -$35.84 M(-13.2%) |
| Sept 1999 | - | -$1.00 M(-93.5%) | -$41.31 M(-20.0%) |
| June 1999 | - | -$15.47 M(+65.8%) | -$51.63 M(+11.8%) |
| Mar 1999 | - | -$9.33 M(-39.8%) | -$46.20 M(-14.1%) |
| Dec 1998 | -$53.81 M(+338.1%) | -$15.51 M(+36.9%) | -$53.81 M(+33.3%) |
| Sept 1998 | - | -$11.33 M(+12.9%) | -$40.37 M(+20.1%) |
| June 1998 | - | -$10.04 M(-40.8%) | -$33.60 M(+11.3%) |
| Mar 1998 | - | -$16.94 M(+717.9%) | -$30.19 M(+145.8%) |
| Dec 1997 | -$12.28 M(+53.5%) | -$2.07 M(-54.6%) | -$12.28 M(+23.9%) |
| Sept 1997 | - | -$4.56 M(-31.2%) | -$9.91 M(+15.9%) |
| June 1997 | - | -$6.62 M(-782.7%) | -$8.55 M(+129.3%) |
| Mar 1997 | - | $970.00 K(+223.3%) | -$3.73 M(-53.4%) |
| Dec 1996 | -$8.00 M(+21.2%) | $300.00 K(-109.4%) | -$8.00 M(-21.6%) |
| Sept 1996 | - | -$3.20 M(+77.8%) | -$10.20 M(+18.6%) |
| June 1996 | - | -$1.80 M(-45.5%) | -$8.60 M(0.0%) |
| Mar 1996 | - | -$3.30 M(+73.7%) | -$8.60 M(+30.3%) |
| Dec 1995 | -$6.60 M(+22.2%) | -$1.90 M(+18.8%) | -$6.60 M(-15.4%) |
| Sept 1995 | - | -$1.60 M(-11.1%) | -$7.80 M(+6.8%) |
| June 1995 | - | -$1.80 M(+38.5%) | -$7.30 M(+10.6%) |
| Mar 1995 | - | -$1.30 M(-58.1%) | -$6.60 M(+22.2%) |
| Dec 1994 | -$5.40 M | -$3.10 M(+181.8%) | -$5.40 M(+134.8%) |
| Sept 1994 | - | -$1.10 M(0.0%) | -$2.30 M(+91.7%) |
| June 1994 | - | -$1.10 M(+1000.0%) | -$1.20 M(+1100.0%) |
| Mar 1994 | - | -$100.00 K | -$100.00 K |
FAQ
- What is Nektar Therapeutics annual free cash flow?
- What is the all time high annual FCF for Nektar Therapeutics?
- What is Nektar Therapeutics annual FCF year-on-year change?
- What is Nektar Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly FCF year-on-year change?
- What is Nektar Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Nektar Therapeutics?
- What is Nektar Therapeutics TTM FCF year-on-year change?
What is Nektar Therapeutics annual free cash flow?
The current annual FCF of NKTR is -$193.47 M
What is the all time high annual FCF for Nektar Therapeutics?
Nektar Therapeutics all-time high annual free cash flow is $703.98 M
What is Nektar Therapeutics annual FCF year-on-year change?
Over the past year, NKTR annual free cash flow has changed by +$116.21 M (+37.53%)
What is Nektar Therapeutics quarterly free cash flow?
The current quarterly FCF of NKTR is -$44.60 M
What is the all time high quarterly FCF for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly free cash flow is $956.90 M
What is Nektar Therapeutics quarterly FCF year-on-year change?
Over the past year, NKTR quarterly free cash flow has changed by -$2.44 M (-5.80%)
What is Nektar Therapeutics TTM free cash flow?
The current TTM FCF of NKTR is -$177.81 M
What is the all time high TTM FCF for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM free cash flow is $912.79 M
What is Nektar Therapeutics TTM FCF year-on-year change?
Over the past year, NKTR TTM free cash flow has changed by +$26.59 M (+13.01%)